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of Chinese herbal extract combinations claiming to treat heart disease.
Methods: Patent documents were retrieved from the official website of the State Intellectual
Property Office of the People’s Republic China. Cluster, frequency, and fuzzy cluster analyses
were applied.
Results: A high number of patents in force included high-frequency herbs such as Salvia mil-
tiorrhiza, Panax ginseng, and Panax notoginseng, as well as high-frequency herbal families
such as Araliaceae, Leguminosae, Labiatae, and Umbelliferae. Herb pairs such as P.
ginseng þ Ophiopogon japonicus, S. miltiorrhiza þ Dalbergia odorifera, and P.
ginseng þ Schisandra chinensis are also commonly used, as well as herbal family pairs such
as Araliaceae þ Liliaceae, Lauraceae þ Leguminosae, and Araliaceae þ Schisandraceae. Tradi-
tional treatment principles for preventing and treating heart diseases was most-commonly
based on simultaneously treating the liver and heart and treating the lung and spleen second-
arily for choosing herbal combinations.
Conclusion: Most of the high-frequency Chinese herbs in the patents investigated belong to the
high-frequency herbal families, and herb pairs were commonly selected to coincide with the
commonly-used herbal family pairs. Low-frequency Chinese herbs were also used, but gener-
ally belonged to the high-frequency herbal families, and were therefore similar to the high-
frequency herbs in terms of traditional categories of taste and channel entered. The results
reflect the use of traditional principles of formula composition, and suggest that these princi-
ples may indeed be an effective guide for further research and development of Chinese herbal64286727.
.cn (S. Xiao), thliu@vip.163.com (T. Liu).
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In China, traditional Chinese herbs have long been used to
treat cardiovascular diseases. In traditional Chinese medi-
cine (TCM), disorders that involve the cardiovascular sys-
tem fall under the rubric of “heart system disease,” and are
also comprised of illnesses involving other biomedical sys-
tems of the body, in particular mental (psychologic) and
brain disorders. According to the World Health Organiza-
tion, an estimated 17.7 million people died from cardio-
vascular diseases in 2015, and this number will continue to
grow to estimated 22.2 million in 2030.1 Because heart
disease is a serious threat to human health, it has become a
focus of research worldwide.
As more and more patients and consumers demand
natural, organic, or side-effect free treatments, the use of
herbal medicine (also known as botanic medicine, or phy-
tomedicine) is increasingly being used to prevent and treat
heart disease. Chinese medicine may have an important
contribution to make in this area. However, TCM has still
not been accepted in many countries. To a large extent,
this is due to problems with safety and stability. Problems
may arise when original medicinal plants or decoction
pieces (semi-processed, dried and cut herbs) from different
geographic regions are used interchangeably without
investigating possible differences in medicinal properties.
The complex chemical composition of the multi-herb
preparations and the lack of clear evidence of their exact
mechanisms of action are also important issues.2,3 Prepared
medicines, typically in pill, powder, or capsule form from
TCM extracts may be a solution to these problems.4,5 Herbal
extracts are a type of TCM product processed by using a
solvent, typically water or ethanol, to release the active
chemical constituents.6 The extract can then be considered
to be a substitute for dried plant matter (decoction pieces)
or as an active ingredient that can be incorporated into
other medicinal products or combination pharmacologic
products. Due to these advantages, TCM extracts have
become more popular in recent years and prescribing Chi-
nese herbal extract combinations has become a new
alternative for herbal administration. As TCM expands
worldwide, many TCM research and development units
have begun to pay more attention to herbal extracts.
Patent in force, or active patent, refers to a patent that
has effective status. Most patent rights cease to exist
before their expiration, due to either the low quality of the
patent, lack of commercialization, or inadequate profit-
ability after commercialization.7 Hence the time that a
patent is maintained is a reliable indicator of the scientific
and technologic innovation capacity and market competi-
tiveness. As one of the most systematic, comprehensive,
and active information resources, patent documents should
not be overlooked as a source of innovative ideas for newdrugs. By studying the technical description of the active
patent of a Chinese herbal extract combination, new
medical resources, including a patent strategy, can be
developed.8
To date, TCM patent document research of Chinese and
overseas offices has mainly focused on Chinese herbal
compounds and extracts to analyze the patentability, pat-
ent protection awareness, or simple bibliometric analysis of
herbal formulas. Although there has been some research on
Chinese herbal compound patents designed to treat car-
diovascular diseases, methods have been limited to simple
bibliometric analyses. We have not found any systematic
statistical analysis and qualitative research on active pat-
ents of Chinese herbal extract combinations for preventing
and treating TCM heart system disease.
Data mining, which is widely used in TCM research, is a
useful tool for investigating the aforementioned patent
documents.9,10 Data mining in the form of cluster analysis
and frequency analysis have been applied to the identifi-
cation of Chinese herbs, studies of the regularity of tradi-
tional Chinese medicinal compounds, classification of
traditional Chinese herbs among other areas.11,12
In this study, we applied frequency analysis, cluster
analysis, and fuzzy cluster analysis to explore the combi-
natorial patterns of Chinese herbal extracts for the treat-
ment of heart system diseases. Our retrieval criteria were
the Chinese equivalent of “Chinese herbal extract combi-
nation patents”. Based on our analysis, suggestions are
made for the development of new drugs.Materials and methods
Patent retrieval and establishment of databases
Patent documents used in this research were retrieved from
the official website of the State Intellectual Property Office
of the People’s Republic of China. There are four query
systems that can be accessed through the website. There-
fore, we believe the information we obtained is accurate
and complete.
According to Chinese patent law, patent applications are
published within 18 months after the earliest priority date
of the patent application. The patents in this study were all
approved, and 2014 was the most recent year with com-
plete coverage of the granted patents. To acquire an
objective perspective on TCM extract combination patents,
active patents granted from 1995 through 2014 were
selected.
Chinese keyword combination was “traditional Chinese
medicine OR Chinese herbs OR natural drugs” AND “extract
OR extractive”. These keyword combinations were identi-
fied through literature survey. Initial search targeted
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manual filtering, patent documents meeting the keyword
criteria were retrieved.
After retrieval, patent documents were eliminated
based on the following exclusion criteria: (1) if proprietary
Chinese medicine was recorded in the herbal extract
combination patent document; (2) if pharmaceutical drugs
were recorded in the patent document; (3) non-human
treatment; (4) disorders other than TCM heart system dis-
eases as verified in Classification and Codes of Diseases and
ZHENG of Traditional Chinese Medicine13; (5) Chinese
herbal extract combinations that were only extracted with
water or ethanol but not separated or purified.
The name, action, property and taste, channel entered,
herbal (botanic) family name of Chinese herbs were
recorded based on guidelines delineated in The Dictionary
of Medicinal Plants.14 A critical part of our investigation
was accurately identifying an herbal extract when more
than one name is used for the same plant. For example, in
our search we used bai shao instead of shao yao for Paeonia
lactiflora.
Microsoft Access (2010) was used to create three data-
basesdpatent information database (PID), Chinese herb
database (CHD), and the combination of Chinese herbal
family database (FCD). PID held the patent numbers,
approval dates, compositions of the Chinese herbal extract
combinations and indications. TCHD held the names, ac-
tions, properties and tastes, channels entered, herbal
family names and classifications of Chinese herbs listed in
the patent document. FCD held the herbal family compo-
sitions of the herbal extract combinations.Investigation of Chinese herbal extract
combination patterns using frequency analysis and
cluster analysis
Frequency analysis of Chinese herbs and herbal families
was performed using IBM SPSS software (version 20.0; IBM,
Armonk, NY, USA) and Microsoft (MS) Access. Analysis was
carried out on the frequency of the Chinese herb utiliza-
tion, channel entered, and herbal families included in
extract combinations to prevent and treat heart system
diseases. The Chinese herbs were then classified based on
the families recorded in The Dictionary of Medicinal Plants.
The frequency of each category was calculated and items
from the high-frequency Chinese herbs and high-frequency
herbal families were enumerated separately. The two data
sets were linked and analyzed to understand the frequency
of the Chinese herb utilization, and to prepare for the next
steps.
Cluster analysis was then performed using SPSS. First,
the query function of MS Access was used to set up the
queries that were extracted from the PID and FCD.
Following quantization, the Chinese herbs or herbal fam-
ilies included in the queries were binary coded and
expressed as 0 or 1 in SPSS (0 Z combination does not
contain the herb; 1 Z combination contains the herb).
Cluster analysis of the Chinese herbs or their families was
based on Q-type hierarchical cluster, and between-group
linkage was chosen as the clustering method. The distance
between two variables was based on the squared Euclideandistance. Finally, a dendrogram was created to represent
the cluster analysis data. A dendrogram is a visual presen-
tation of the hierarchical categories of a set of items that
have shared characteristics.
Fuzzy cluster analysis of herbs in the same family was
accomplished with SPSS as well. First, MS Access was used
to set up the queries of Chinese herbs that belonged to
high-frequency herbal families, and were identified as
treatments for heart system disease for further fuzzy
cluster analysis (Queries were retrieved from the CHD).
After quantization, the name of the Chinese herbs included
in the queries were recorded, their properties and tastes
and channel entered of the Chinese herbs included in the
queries were recorded as the variables and were binary
coded and expressed as 0 or 1 in SPSS. (0 Z Chinese herb
does not have this nature; 1 Z Chinese herb has this na-
ture). Fuzzy cluster analysis of the Chinese herbs in the
same herbal family was based on Q-type hierarchical clus-
ter, Ward’s method was chosen as the clustering method,
distance between two variables was based on squared
Euclidean distance, and the data shown as a dendrogram.
Results and discussion
Frequency analysis
Chinese herbs and herbal families
During 1995e2014, a total of 1971 Chinese herbs were
included in active patents that claimed they could prevent
and treat heart system disease. We found that there were
20 Chinese herbs defined as high-frequency herbs for which
the utilization frequency number was greater than 20 times
(Table 1). These 20 herbs together accounted for approxi-
mately 50% of the total. Among them, the most frequently
used Chinese herbs were Salvia miltiorrhiza, Panax
ginseng, Panax notoginseng, Astragalus membranaceus,
and Ligusticum chuanxiong. These coincided with high-
frequency herbal families d of which the four highest-
frequency families were Araliaceae, Leguminosae, Labi-
atae, and Umbelliferae. Sixteen herbal families were
identified as high-frequency families, and the utilization
frequency number was greater than 30 times for each
family (Table 2). These 16 families together accounted for
approximately 74% of the total. In addition, there were
many Chinese herbs that were used only once or twice,
such as Panax japonicus (1), Caragana intermedia (1),
Leonurus japonicus (1), Foeniculum vulgare (1), Peuceda-
num praeruptorum (2), Lilium lancifolium (2) and Sophora
japonica (2).
The actions of the highest-frequency Chinese herbs have
been confirmed by pharmacologic research. Their active
ingredients are largely comprised of polyphenols (such as
flavonoids and phenolic acids) and saponins, such as
astragaloside IV, icariin, ginsenoside, paeoniflorin, total
flavonoids from Dalbergia odorifera, butein, and salvianolic
acid B.15e17 There are also other active ingredients such as
tanshinone II and glycolipid from Polygala tenuifolia.18
Some common herbs are described below.
S. miltiorrhiza. Active constituents are lipid-soluble
tanshinone I (Tan I), tanshinone IIA (Tan II A), cryptotan-
shinone, and dihydrotanshinone as well as water-soluble
Table 1 High-frequency Chinese herbs to prevent and
treat heart system disease.
Rank Latin herb name Herbal family
name
Frequency
number
1 Salvia miltiorrhiza
Bunge
Labiatae 141
2 Panax ginseng C. A. Mey Araliaceae 94
3 Panax notoginseng
(Burk) F. H. Chen ex C.
Chow
Araliaceae 90
4 Astragalus
membranaceus Bunge
Leguminosae 73
5 Borneolum syntheticum
(sourced from
Dipterocarpus
turbinatus C.F.Gaertn)
Lauraceae 66
6 Ligusticum chuanxiong
Hort.
Umbelliferae 64
7 Schisandra chinensis
(Turcz.) Baill.
Schisandraceae 60
8 Ophiopogon japonicus
(Thunb.) Ker-Gawl.
Liliaceae 59
9 Angelica sinensis (Oliv.)
Diels
Umbelliferae 46
10 Paeonia lactiflora Pall. Ranunculaceae 35
11 Epimedium
brevicornum Maxim.
Berberidaceae 33
12 Dalbergia odorifera T.
Chen.
Leguminosae 33
13 Carthamus tinctorius L. Compositae 33
14 Rehmannia glutinosa
(Gaertn.) Libosch. ex
Fisch. et Mey.
Scrophulariaceae 32
15 Glycyrrhiza uralensis
Fisch
Leguminosae 29
16 Pueraria lobata (Willd.)
Ohwi
Leguminosae 27
17 Ginkgo biloba L. Ginkgoaceae 25
18 Poria cocos (Schw.)
Wolf.
Polyporaceae 24
19 Acorus tatarinowii
Schott
Araceae 21
20 Polygala tenuifolia
Willd.
Polygalaceae 21
Table 2 High-frequency herbal families to prevent and
treat heart system disease.
Rank Herbal family name Frequency number
1 Araliaceae 218
2 Leguminosae 190
3 Labiatae 173
4 Umbelliferae 129
5 Medicinal animal components 127
6 Lauraceae 93
7 Ranunculaceae 88
8 Liliaceae 82
9 Compositae 74
10 Schisandraceae 60
11 Rosaceae 45
12 Scrophulariaceae 44
13 Zingiberaceae 38
14 Polygonaceae 37
15 Berberidaceae 33
16 Rubiaceae 30
84 J. Cheng et al.danshensu and salvianolic acid B (SAB). S. miltiorrhiza has
been found to have a cardioprotective effect: SAB inhibits
platelet adhesion to collagen19; Tan IIA downregulates
protein expression and the activities of matrix
metalloproteinase-2 and 9 and reduces VCAM-1 and 1L-1b
levels to suppress increase in the aorta intimal area in
rabbits induced with cardiovascular disease by being fed a
high-fat-diet.20
P. ginseng and P. notoginseng. Both of these herbs are
used for treating heart system disease. Their extracts e
ginsenosides and P. notoginseng saponins (PNS) e contain
ginsenoside-Rb1, ginsenoside-Rg1 and ginsenoside-Re. Gin-
senoside-Rb1 and ginsenoside-Re have been shown to be
active ingredients based on their neuroprotective effects
and protection against cerebral ischemia-reperfusion injuryin rats; the preventive effect of ginsenoside-Rb1 is more
significant than the repair effect.21 PNS appears to promote
proliferation, enhance ALP activity and calcium deposition,
as well as induce differentiation tendency toward osteo-
blasts in NIH3T3 cells.15
L. chuanxiong.22,23 In ICR mice, forebrain ischemic injury
can be reduced by Z-liguestilide, which is the main lipo-
philic component of L. chuanxiong, indicating that Z-lig-
uestilide may help prevent cardiovascular disease.
Angiotensin II-induced VSMC proliferation is significantly
inhibited by ferulic acid, which is the active ingredient of L.
chuanxiong, in a dose-dependent manner, indicating that
ferulic acid may help prevent cardiovascular disease.
A. membranaceus.24 The active ingredients of A. mem-
branaceus are Astragalus saponins, Astragalus poly-
saccharide, and Astragalus flavone. A. membranaceus has
the highest content of astragaloside IV among all saponins
and shows a protective effect against ischemic heart and
brain injury.
Additionally, many of the low-frequency Chinese herbs
that belong to the high-frequency herbal families have also
been identified to have positive effects on the cardiovas-
cular system. The major active ingredients are similar to
those of the high-frequency Chinese herbs. Herbal families
and their major active ingredients are18,25e29: in Aral-
iaceae, the major active ingredients of P. japonicus are
saponins; in Labiatae, the major active ingredients of L.
japonicus are flavonoids; in Leguminosae, the major active
ingredients of C. intermedia are flavonoids, and the major
active ingredients of Psoralea corylifolia are flavonoids and
the meroterpene bakuchiol; in Umbelliferae, the major
active ingredients of F. vulgare are volatile oils; in Lil-
iaceae, the major active ingredients of L. lancifolium are
steroidal saponins and polysaccharides.
Channel entered of the Chinese herbs
TCM theory holds that each herb is associated with a
channel(s) of the body, that is, the herb’s action enters the
channel(s). Some call this the herb’s meridian tropism. The
heart system disease herbs listed in this article are ones in
Table 3 Channel entered frequency of Chinese herbs
identified to prevent and treat heart system diseases.
Channel entered Frequency number (%)
Liver 1174 (20.9)
Heart 1137 (20.5)
Lung 802 (14.4)
Spleen 760 (13.5)
Kidney 605 (10.9)
Stomach 488 (8.5)
Large intestine 231 (4.0)
Pericardium 220 (4.0)
Gallbladder 131 (2.3)
Bladder 46 (0.8)
Small intestine 4 (0.1)
Triple energizer 4 (0.1)
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the lung and spleen for secondary support (Table 3). All of
the herbs in Table 1 enter the liver or heart channel,
meaning that they have specific effects on the functioning
of these channels and can treat diseases associated with
these channels. The exceptions are A. membranaceus,
Ginkgo biloba, and Pueraria lobata, which act on the lung
and spleen channels.
Cluster analysis identifying the most common herb
pairs and the most common herbal family pairs
In TCM, herbal prescriptions are combinations of herbs that
are chosen based on the patient’s condition and the proper-
ties of both the individual herbs and the formula as a whole.Figure 1 Dendrogram of cluster analysis of Chinese herbal extrThe herb pair, or two herbs that are combined to increase or
decrease certain effects, is the basic unit in a prescription.
Our analysis showed that herb pairs commonly-used to pre-
vent and treat heart system disease are: P. notoginseng þ S.
miltiorrhiza; S. miltiorrhiza þ Borneolum syntheticum; P.
ginseng þ Schisandra chinensis; P. ginseng þ Ophiopogon
japonicus; S. chinensis þ O. japonicus; S. miltiorrhiza þ D.
odorifera; D. odorifera þ Borneolum syntheticum; L.
chuanxiong þ Carthamus tinctorius; Angelica sinensis þ P.
lactiflora; L. chuanxiong þ P. lactiflora; and P. tenuifolia
þ Acorus tatarinowii (Fig. 1). Common three-herb combina-
tions are: S. chinensis þ O. japonicus þ P. ginseng; A.
sinensis þ P. lactiflora þ C. tinctorius; and Poria cocos þ A.
tatarinowii þ P. tenuifolia.
Common herbal family pairs used for preventing and
treating heart system disease are: Araliaceae þ Liliaceae;
Lauraceae þ Labiatae; Schisandraceae þ Araliaceae;
Umbelliferaeþ Ranunculaceae; Schisandraceaeþ Liliaceae;
Labiatae þ Leguminosae; Lauraceae þ Leguminosae;
Rubiaceae þ Zingiberaceae; Berberidaceae þ Scrophul
ariaceae; and Zingiberaceae þ Ranunculaceae (Fig. 2).
Fuzzy cluster analysis revealed that most of the common
herb pairs also belong to common herbal family pairs.
However, the common herbal family pairs do not include all
of the common herb pairs.
Most of the common herb pairs are derived from classical
TCM prescriptions. For example, the prescription Emperor
of Heaven’s Special Pill to Tonify the Heart (tian wang bu
xin dan), which dates to 17th century Ming dynasty, con-
tains the herb pairs O. japonicus þ P. ginseng and P.
ginseng þ S. chinensis. Another prescription from 19th
century Qing dynasty is Drive Out Stasis from the Mansion of
Blood Decoction (xue fu zhu yu tang), contains the herbact combinations to prevent and treat heart system disease.
Figure 2 Dendrogram of cluster analysis of herbal families to prevent and treat heart system disease.
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flora, A. sinensis þ L. chuanxiong, and L. chuanxiong þ P.
lactiflora. Yet another example is Tonify the Yang to
Restore Five [-Tenths] Decoction (bu yang huan wu tang), a
prescription that also dates to 19th century Qing dynasty,
contains the herb pairs A. membranaceus þ A. sinensis and
A. membranaceus þ P. lactiflora.30
In the tradition of Chinese medicine, it is believed that
classical prescriptions have been handed down and persist
because they are based on accumulated clinical experience
of generations of practitioners. Therefore, the applications
and clinical efficacy of herb pairs should not be under-
estimated. Based on fuzzy cluster analysis of the patents
we investigated, we can only speculate on the massive
possibility of the combinations of Chinese herb extracts for
future research and development.Fuzzy cluster analysis of Chinese herbs in the same
family
Because few Chinese herbs recorded in the patent docu-
ments for the prevention and treatment of heart system
disease belong to the Lauraceae (4), Schisandraceae (1) and
Ranunculaceae families (5), we performed analysis on a
select set of families: Araliaceae, Labiatae, Umbelliferae,
Liliaceae, and Leguminosae.
Based on fuzzy cluster analysis, some herbs belong to
the same category, which is showed similarity in taste and
channel entered: in Araliaceae, P. ginseng, Radix ginseng
rubra (steamed P. ginseng) and P. japonicus belong to the
same category (Fig. 3). In Umbelliferae, L. chuanxiong,
Ligusticum sinense, and F. vulgare belong to the same
category (Fig. 4). In Labiatae, S. miltiorrhiza and A.membranaceus, Scutellaria barbata and L. japonicus, L.
japonicus fruit, Prunella vulgaris and Ajuga decumbens
belong to the same categories (Fig. 5). However, the three
categories can also be included under the same larger
category when the Chinese herbs from Labiatae are clus-
tered into three categories. In Leguminosae, P. corylifolia,
D. odorifera and Erythrina variegata, A. membranaceus
and C. intermedia belong to the same categories (Fig. 6). In
Liliaceae, O. japonicus and Fritillaria thunbergii, Fritil-
laria cirrhosa, Rohdea japonica and Lilium lancifolium
belong to the same categories (Fig. 7).
We found that within the same family, there are many
low-frequency Chinese herbs that are similar to high-
frequency herbs in terms of taste and channel entered, and
many of these herbs have similar active ingredients and ap-
plications. For example, P. ginseng and P. japonicus are both
slightlywarm in nature, and sweet and slightly bitter in taste,
enter the lung and spleen channels, and both have saponins
as active ingredients. Their difference is that P. ginseng also
has affinity for the heart and kidney channels, but P. japo-
nicus also has affinity for the liver channel. As another
example, A. membranaceus and C. intermedia are both
warm and sweet in taste and enter the spleen channel, and
have saponins and flavones as active ingredients. Their dif-
ference is that A. membranaceus also acts on the lung
channel, but C. intermedia also acts on the liver channel.Study limitations
This study has several limitations. First, the database
sample size was limited due to the fact that Chinese herbal
extract combinations are a new type of formulation
developed about 20 years ago. As such, the number of
Figure 3 Dendrogram of fuzzy cluster analysis of herbs in the Araliaceae family.
Figure 4 Dendrogram of the fuzzy cluster analysis of herbs in Umbelliferae family.
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nese herbs and common herb pairs in this study may not
only be used for the prevention and treatment heart system
disease. For example, S. miltiorrhiza is also commonly usedto treat liver system disease. This might be because the
extractive fractions in this herb that treat heart system
disease are different from the fractions that treat liver
system disease. Third, the scope of symptoms is wide.
Figure 5 Dendrogram of fuzzy cluster analysis of herbs in the Labiatae family.
Figure 6 Dendrogram of fuzzy cluster analysis of herbs in Leguminosae family.
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ZHENG of Traditional Chinese Medicine13 a professional
standard for TCM, heart system diseases encompass many
conditions that are considered in biomedicine to belong toother systems of the body such as mental disorders (e.g.,
depression) and brain disorders (e.g., dementia). Moreover,
in TCM, these disorders are often related to each other in
terms of traditional categories of disease causation and
Figure 7 Dendrogram of fuzzy cluster analysis of herbs in Liliaceae family.
Chinese herbal extract combinations to treat heart disease 89development. Thus, further laboratory and clinical studies
are needed to confirm which specific biomedical diseases
can be prevented and treated with the high-frequency
Chinese herbs and common herbal pairs in this study.
Finally, patent documents are a unique scientific and
technical literature with advantages and disadvantages.
For example, the dosage or the dosage ratio of the herbal
extract combinations is typically represented as a numeri-
cal range. Therefore, further study is needed to confirm the
optimal and specific dosages.
Conclusions
In summary, from the active patents we accessed at the
State Intellectual Property Office of the People’s Republic
of China, common traditional Chinese herbs in herbal
extract combinations used to prevent and treat heart sys-
tem diseases are S. miltiorrhiza, P. ginseng and P. noto-
ginseng. Common herb pairs include P. notoginseng þ S.
miltiorrhiza, S. miltiorrhiza þ Borneolum syntheticum, P.
ginseng þ S. chinensis. Herbal extract combinations appear
to agree with that of high-frequency herbal families and
herbal family pairs. Additionally, the herbs seem to have
been selected based on the principles of treating the liver,
heart, lung and spleen, as they are understood in TCM.
Furthermore, focusing on low-frequency Chinese herbs
that belong to high-frequency herbal families, such as P.
japonicus, L. japonicus, Caragana intermedia, and inves-
tigating low-frequency herbs combined with high-
frequency herbal family pairs may to development new
herb pairs and Chinese medicines to prevent and treat
heart system diseases.Because the material foundation of efficacy is more
clearly elucidated than the efficacy of a whole Chinese
herbal compound, Chinese herbal extract combinations
possess higher stability, safety, and controllability. This
may explain why foreign patent applications by TCM en-
terprises have increased in recent years. We conclude that
Chinese herbal extract combinations may become a signif-
icant medicinal product and that there is great potential for
their international development.
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